Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-12-20

FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for dapagliflozin and metformin hydrochloride, enabling a fixed-dose combination product for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin and metformin hydrochloride (dapagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)